Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Resiquimod by SURGE Therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Resiquimod is under clinical development by SURGE Therapeutics and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC)...
Data Insights
Resiquimod by SURGE Therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Resiquimod is under clinical development by SURGE Therapeutics and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC)...